1
|
de Melo-Martín I, Ortega-Paíno E. Biobanking Legislation in Spain: Advancing or Undermining Its Ethical Values? Biopreserv Biobank 2024; 22:242-247. [PMID: 38237124 PMCID: PMC11301700 DOI: 10.1089/bio.2023.0107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/27/2024] Open
Abstract
Biobanks are important resources for improving public health and individual care. Some legal frameworks can be more or less conducive to advancing the potential benefits of biobanks. The purpose of this article is to assess biobanking legislation and practices in Spain to determine how well they fare in such a regard. We focus here on some of the primary ethical values that ground relevant legislation and that we believe are consistent with promoting biobanking benefits: the value of scientific research; efficient use of scarce resources; and respect for the dignity of donors. We argue that although Spanish regulations advance these values in important ways, they also have provisions that undermine them and thus risk limiting the potential benefits of biobanks. We offer some suggestions for improvement.
Collapse
Affiliation(s)
- Inmaculada de Melo-Martín
- Division of Medical Ethics, Weill Cornell Medical College, Cornell University, New York, New York, USA
| | - Eva Ortega-Paíno
- Centro Nacional de Investigaciones Oncológicas (CNIO), Biobanco, Madrid, Spain
| |
Collapse
|
2
|
Rounds CC, Li C, Zhou W, Tichauer KM, Brankov JG. A cadaveric breast cancer tissue phantom for phase-contrast X-ray imaging applications. Animal Model Exp Med 2023; 6:427-432. [PMID: 37859563 PMCID: PMC10614119 DOI: 10.1002/ame2.12340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 07/19/2023] [Indexed: 10/21/2023] Open
Abstract
BACKGROUND As mammography X-ray imaging technologies advance and provide elevated contrast in soft tissues, a need has developed for reliable imaging phantoms for use in system design and component calibration. In advanced imaging modalities such as refraction-based methods, it is critical that developed phantoms capture the biological details seen in clinical precancerous and cancerous cases while minimizing artifacts that may be caused due to phantom production. This work presents the fabrication of a breast tissue imaging phantom from cadaveric breast tissue suitable for use in both transmission and refraction-enhanced imaging systems. METHODS Human cancer cell tumors were grown orthotopically in nude athymic mice and implanted into the fixed tissue while maintaining the native tumor/adipose tissue interface. RESULTS The resulting human-murine tissue hybrid phantom was mounted on a clear acrylic housing for absorption and refraction X-ray imaging. Digital breast tomosynthesis was also performed. CONCLUSION Both attenuation-based imaging and refraction-based imaging of the phantom are presented to confirm the suitability of this phantom's use in both imaging modalities.
Collapse
Affiliation(s)
- Cody C. Rounds
- Biomedical EngineeringIllinois Institute of TechnologyChicagoIllinoisUSA
- Medical Imaging Research CenterIllinois Institute of TechnologyChicagoIllinoisUSA
| | - Chengyue Li
- Biomedical EngineeringIllinois Institute of TechnologyChicagoIllinoisUSA
- Medical Imaging Research CenterIllinois Institute of TechnologyChicagoIllinoisUSA
| | - Wei Zhou
- Biomedical EngineeringIllinois Institute of TechnologyChicagoIllinoisUSA
- Medical Imaging Research CenterIllinois Institute of TechnologyChicagoIllinoisUSA
| | - Kenneth M. Tichauer
- Biomedical EngineeringIllinois Institute of TechnologyChicagoIllinoisUSA
- Medical Imaging Research CenterIllinois Institute of TechnologyChicagoIllinoisUSA
| | - Jovan G. Brankov
- Biomedical EngineeringIllinois Institute of TechnologyChicagoIllinoisUSA
- Medical Imaging Research CenterIllinois Institute of TechnologyChicagoIllinoisUSA
- Electrical and Computer EngineeringIllinois Institute of TechnologyChicagoIllinoisUSA
| |
Collapse
|
3
|
Slušná ĽK, Balog M. Review of Indicators in the Context of Biobanking. Biopreserv Biobank 2023; 21:318-326. [PMID: 36099204 DOI: 10.1089/bio.2022.0073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background: Biobanks that intend to serve as high-performing and stable elements of an innovative research ecosystem must have an established system for regular measurement and evaluation using appropriately set indicators. The main objective of this study was to provide a comprehensive overview of indicators in the context of biobanking, with new perspectives to highlight the existence of numerous options and introduce indicators that could help overcome problems associated with the difficult assessment of the impact of biobanks. Methods: A literature review was performed to identify publications relevant to the topic of indicators in biobanking. The Web of Science Core Collection and PubMed databases were searched using specific keywords. In addition, three articles that focused on indicators designed for the evaluation of research infrastructures were included in the review. Results: Based on the scientific literature for the biobanking field, many types of quantitative and qualitative indicators exist. They are mainly related to the quantity and quality of data and samples, their distribution, the monitoring of research projects, and subsequent publication outputs. The indicators identified in the biobanking literature primarily focus on the outcome, not the impact. Conclusions: Indicators identified in the biobanking literature may be further expanded with suggestions designed for other types of research infrastructures, while considering the context where biobanks operate and the needs of individual biobanking stakeholders. The establishment of a comprehensive monitoring system that captures all necessary elements is crucial for modern biobanks.
Collapse
Affiliation(s)
| | - Miroslav Balog
- Centre of Social and Psychological Sciences, SAS, Bratislava, Slovakia
| |
Collapse
|
4
|
López JE, Kyle A, Hosseini AJ, Wilson M, Soares S. Educational video while "waiting-to-be-seen" in a cardiology outpatient clinic promotes opt-in self-consent for biobanking of remnant clinical biospecimens: A randomized-controlled trial. J Clin Transl Sci 2023; 7:e103. [PMID: 37250987 PMCID: PMC10225258 DOI: 10.1017/cts.2023.518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 03/12/2023] [Accepted: 03/26/2023] [Indexed: 05/31/2023] Open
Abstract
Objectives Consenting donors for remnant clinical biospecimen donation is critical for scaling research biorepositories. Opt-in, low-cost, self-consenting for donations that solely relied on clinical staff and printed materials was recently shown to yield ∼30% consent rate. We hypothesized that adding an educational video to this process would improve consent rates. Methods Randomized patients (by clinic day) in a Cardiology clinic received either printed materials (control) or the same materials plus an educational video on donations (intervention) while waiting to be seen. Engaged patients were surveyed at the clinic checkout for an "opt-in" or "opt-out" response. The decision was documented digitally in the electronic medical record. The primary outcome of this study was the consent rate. Results Thirty-five clinic days were randomized to intervention (18) or control (17). Three hundred and fifty-five patients were engaged, 217 in the intervention and 158 in the control. No significant demographic differences were noted between treatment groups. Following an intention-to-treat analysis, the rate of opt-in for remnant biospecimen donation was 53% for the intervention and 41% for the control group (p-value = 0.03). This represents a 62% increase in the odds of consenting (OR = 1.62, 95% CI = 1.05-2.5). Conclusion This is the first randomized trial showing that an educational video is superior to printed materials alone when patients are self-consenting for remnant biospecimen donation. This result adds to the evidence that efficient and effective consenting processes can be integrated into clinical workflows to advance universal consenting in medical research.
Collapse
Affiliation(s)
| | - Andrew Kyle
- Division of Internal Medicine at UC Davis, CA, USA
| | | | - Machelle Wilson
- Clinical Translational Science Center, University of California Davis Medical Center, Sacramento, CA, USA
| | - Stephanie Soares
- Clinical Translational Science Center, University of California Davis Medical Center, Sacramento, CA, USA
| |
Collapse
|
5
|
Zhang Y, Bian Z, Chen Y, Jiang E, Chen T, Wang C. Positive association between research competitiveness of Chinese academic hospitals and the scale of their biobanks: A national survey. Clin Transl Sci 2022; 15:2909-2917. [PMID: 36177952 PMCID: PMC9747119 DOI: 10.1111/cts.13408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2022] [Revised: 08/10/2022] [Accepted: 08/16/2022] [Indexed: 01/26/2023] Open
Abstract
Biobanks are important research infrastructure developed rapidly by Chinese hospitals. The objective of this study is to investigate the association between the comprehensive research competitiveness of hospitals and the development of hospital biobanks. In 2018, we conducted a national survey among Chinese biobank managers and directors. An online questionnaire was used to collect data of biobank characteristics. Of the 70 academic hospital biobanks responded to our survey, 49 of their hospitals were listed in the Science and Technology Evaluation Metrics (STEM) and 46 of their hospitals were listed in the Fudan Hospital Rankings, respectively, in 2018. Hospital scores from the STEM and Fudan Hospital Rankings were identified from their official websites. Multivariate linear regression analyses were used to assess the associations of STEM scores and Fudan Hospital Rankings with the scale of biobanks. The overall STEM score, Scientific and Technological Output, and Academic Impact in hospitals with large-scale biobanks were 48.35%, 55.16%, and 58.65% higher than those with small-scale biobanks, respectively. The scale of biobanks was positively associated with STEM score (β = 0.367, p = 0.009), Scientific and Technological Output (β = 0.441, p = 0.001), and Academic Impact (β = 0.304, p = 0.044) after adjustment for potential confounders. For Fudan Hospital Rankings, the comprehensive score and sustainable development ability score were higher in hospitals with large-scale biobanks. Further analyses showed that the scale of the biobanks was positively associated with a higher comprehensive score (β = 0.313, p = 0.037) and a sustainable development ability score (β = 0.463, p < 0.001). The scale of hospital biobanks was positively associated with the research competitiveness of Chinese hospitals.
Collapse
Affiliation(s)
- Yinan Zhang
- Shanghai Jiao Tong University Affiliated Sixth People's HospitalThe Metabolic Disease BiobankShanghaiChina
| | - Zhouliang Bian
- The Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of MedicineShanghaiChina
| | - Yuanyuan Chen
- Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of Digestive System Tumor of Zhejiang ProvinceTaizhou Hospital of Zhejiang ProvinceZhejiangChina,Biological Resource Center, Taizhou Hospital of Zhejiang ProvinceWenzhou Medical UniversityZhejiangChina
| | - Erpeng Jiang
- Shanghai International Medical CenterShanghaiChina
| | - Tianlu Chen
- Center for Translational Medicine and Shanghai Key Laboratory of Diabetes MellitusShanghai Jiao Tong University Affiliated Sixth People's HospitalShanghaiChina
| | - Congrong Wang
- Department of Endocrinology & Metabolism, Shanghai Fourth People's Hospital, School of MedicineTongji UniversityShanghaiChina
| |
Collapse
|
6
|
Willers C, Lynch T, Chand V, Islam M, Lassere M, March L. A Versatile, Secure, and Sustainable All-in-One Biobank-Registry Data Solution: The A3BC REDCap Model. Biopreserv Biobank 2021; 20:244-259. [PMID: 34807733 DOI: 10.1089/bio.2021.0098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Introduction: A key element in the big data revolution is large-scale biobanking and the associated development of high-quality data collections and supporting informatics solutions. As such, in establishing the Australian Arthritis and Autoimmune Biobank Collaborative (A3BC), we sought to establish a low-cost, nation-scale data management system capable of managing a multisite biobank registry with complex longitudinal sample and data requirements. Materials and Methods: We assessed several international commercial and nonprofit software platforms using standardized system requirement criteria and follow-up interviews. Vendor compliance scoring was prioritized to meet our project-critical requirements. Consumer/end-user codesign was integral to refining our system requirements for optimized adoption. Customization of the selected software solution was performed to optimize field auto-population between participant timepoints and forms, using modules that are transferable and that do not impact core code. Institutional and independent testing was used to ensure data security. Results: We selected the widely used research web application Research Electronic Data Capture (REDCap), which is "free" (under nonprofit license agreement terms), highly configurable, and customizable to a variety of biobank and registry needs and can be developed/maintained by biobank users with modest IT skill, time, and cost. We created a secure, comprehensive participant-centric biobank-registry database that includes: (1) best practice data security measures (incl. multisite access login using institutional user credentials), (2) permission-to-contact and dynamic itemized electronic consent, (3) a complete chain of custody from consent to longitudinal biospecimen data collection to publication, (4) complex longitudinal patient-reported surveys, (5) integration of record-level extracted/linked participant data, (6) significant form auto-population for streamlined data capture, and (7) native dashboards for operational visualizations. Conclusion: We recommend the versatile, reusable, and sustainable informatics model we have developed in REDCap for prospective chronic disease biobanks or registry biobanks (of local to national complexity) supporting holistic research into disease prediction, precision medicine, and prevention strategies.
Collapse
Affiliation(s)
- Craig Willers
- Institute of Bone and Joint Research, The Australian Arthritis and Autoimmune Biobank Collaborative, Kolling Institute, University of Sydney, Sydney, Australia
| | - Tom Lynch
- Institute of Bone and Joint Research, The Australian Arthritis and Autoimmune Biobank Collaborative, Kolling Institute, University of Sydney, Sydney, Australia
| | - Vibhasha Chand
- Public Health and Preventive Medicine, Monash University, Clayton, Australia
| | - Mohammad Islam
- Information and Communications Technology, University of Sydney, Sydney, Australia
| | - Marissa Lassere
- School of Population Health, University of New South Wales, Sydney, Australia
| | - Lyn March
- Institute of Bone and Joint Research, The Australian Arthritis and Autoimmune Biobank Collaborative, Kolling Institute, University of Sydney, Sydney, Australia
- Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia
| |
Collapse
|
7
|
Sanderson-November M, Silver S, Hooker V, Schmelz M. Biorepository best practices for research and clinical investigations. Contemp Clin Trials 2021; 116:106572. [PMID: 34583056 DOI: 10.1016/j.cct.2021.106572] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Revised: 09/08/2021] [Accepted: 09/17/2021] [Indexed: 11/24/2022]
Abstract
Translational research requires good quality specimens to ensure the integrity of research results. Clinical research must rely not only on quality specimens, but as well on clinical annotation for consistent, accurate and verifiable scientific and clinical outcomes. In laboratory research performed on a specimen by a single investigator, quality control is easily maintained. In a multi-site clinical research network, the numerous steps for biospecimens from procurement through transport, processing, storage and ultimately testing requires strict standardization of operational workflows and procedures. The practices of a central biorepository can inform and contribute to best practices regarding clinical research specimen integrity for multi-site clinical research.
Collapse
Affiliation(s)
| | - Sylvia Silver
- Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, District of Columbia, United States of America.
| | - Vanessa Hooker
- Department of Pathology, University of Arizona, Tucson, Arizona, United States of America
| | - Monika Schmelz
- Department of Pathology, University of Arizona, Tucson, Arizona, United States of America.
| |
Collapse
|
8
|
Quinn CM, Porwal M, Meagher NS, Hettiaratchi A, Power C, Jonnaggadala J, McCullough S, Macmillan S, Tang K, Liauw W, Goldstein D, Zeps N, Crowe PJ. Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to Sustainability. Biomark Insights 2021; 16:11772719211005745. [PMID: 35173407 PMCID: PMC8842439 DOI: 10.1177/11772719211005745] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Accepted: 03/08/2021] [Indexed: 12/15/2022] Open
Abstract
Human biobanks are recognised as vital components of translational research infrastructure. With the growth in personalised and precision medicine, and the associated expansion of biomarkers and novel therapeutics under development, it is critical that researchers can access a strong collection of patient biospecimens, annotated with clinical data. Biobanks globally are undertaking transformation of their operating models in response to changing research needs; transition from a ‘classic’ model representing a largely retrospective collection of pre-defined specimens to a more targeted, prospective collection model, although there remains a research need for both models to co-exist. Here we introduce the Health Science Alliance (HSA) Biobank, established in 2012 as a classic biobank, now transitioning to a hybrid operational model. Some of the past and current challenges encountered are discussed including clinical annotation, specimen utilisation and biobank sustainability, along with the measures the HSA Biobank is taking to address these challenges. We describe new directions being explored, going beyond traditional specimen collection into areas involving bioimages, microbiota and live cell culture. The HSA Biobank is working in collaboration with clinicians, pathologists and researchers, piloting a sustainable, robust platform with the potential to integrate future needs.
Collapse
Affiliation(s)
- Carmel M Quinn
- Translational Cancer Research Network (TCRN), UNSW Sydney, NSW, Australia
- Prince of Wales Clinical School, UNSW Medicine and Health, UNSW Sydney, NSW, Australia
- Adult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Australia
| | - Mamta Porwal
- Translational Cancer Research Network (TCRN), UNSW Sydney, NSW, Australia
- Prince of Wales Clinical School, UNSW Medicine and Health, UNSW Sydney, NSW, Australia
- Adult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Australia
| | - Nicola S Meagher
- Adult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Australia
- School of Women’s and Children’s Health, UNSW Medicine and Health, UNSW Sydney, NSW, Australia
| | - Anusha Hettiaratchi
- UNSW Biorepository, Mark Wainwright Analytical Centre, UNSW Sydney, Australia
| | - Carl Power
- Biological Resources Imaging Laboratory, Mark Wainwright Analytical Centre, UNSW Sydney, Australia
| | - Jitendra Jonnaggadala
- Translational Cancer Research Network (TCRN), UNSW Sydney, NSW, Australia
- Prince of Wales Clinical School, UNSW Medicine and Health, UNSW Sydney, NSW, Australia
- Adult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Australia
- School of Population Health, UNSW Medicine and Health, UNSW Sydney, NSW, Australia
| | | | - Stephanie Macmillan
- Translational Cancer Research Network (TCRN), UNSW Sydney, NSW, Australia
- Prince of Wales Clinical School, UNSW Medicine and Health, UNSW Sydney, NSW, Australia
- Adult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Australia
| | - Katrina Tang
- NSW Health Pathology, South-East Sydney Local Health District, NSW, Australia
| | - Winston Liauw
- Cancer Care Clinic, St George Hospital, NSW, Australia
| | - David Goldstein
- Translational Cancer Research Network (TCRN), UNSW Sydney, NSW, Australia
- Prince of Wales Clinical School, UNSW Medicine and Health, UNSW Sydney, NSW, Australia
- Adult Cancer Program, Lowy Cancer Research Centre, UNSW Sydney, Australia
- Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia
| | - Nikolajs Zeps
- Epworth Healthcare, VIC, Australia
- Eastern Clinical School, Monash University, Clayton, VIC, Australia
| | - Philip J Crowe
- Prince of Wales Clinical School, UNSW Medicine and Health, UNSW Sydney, NSW, Australia
- Department of Surgery, Prince of Wales Hospital, Randwick, NSW, Australia
| |
Collapse
|
9
|
do Canto AM, Donatti A, Geraldis JC, Godoi AB, da Rosa DC, Lopes-Cendes I. Neuroproteomics in Epilepsy: What Do We Know so Far? Front Mol Neurosci 2021; 13:604158. [PMID: 33488359 PMCID: PMC7817846 DOI: 10.3389/fnmol.2020.604158] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Accepted: 12/09/2020] [Indexed: 12/12/2022] Open
Abstract
Epilepsies are chronic neurological diseases that affect approximately 2% of the world population. In addition to being one of the most frequent neurological disorders, treatment for patients with epilepsy remains a challenge, because a proportion of patients do not respond to the antiseizure medications that are currently available. This results in a severe economic and social burden for patients, families, and the healthcare system. A characteristic common to all forms of epilepsy is the occurrence of epileptic seizures that are caused by abnormal neuronal discharges, leading to a clinical manifestation that is dependent on the affected brain region. It is generally accepted that an imbalance between neuronal excitation and inhibition generates the synchronic electrical activity leading to seizures. However, it is still unclear how a normal neural circuit becomes susceptible to the generation of seizures or how epileptogenesis is induced. Herein, we review the results of recent proteomic studies applied to investigate the underlying mechanisms leading to epilepsies and how these findings may impact research and treatment for these disorders.
Collapse
Affiliation(s)
- Amanda M. do Canto
- Department of Medical Genetics and Genomic Medicine, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
- Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas, Brazil
| | - Amanda Donatti
- Department of Medical Genetics and Genomic Medicine, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
- Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas, Brazil
| | - Jaqueline C. Geraldis
- Department of Medical Genetics and Genomic Medicine, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
- Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas, Brazil
| | - Alexandre B. Godoi
- Department of Medical Genetics and Genomic Medicine, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
- Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas, Brazil
| | - Douglas C. da Rosa
- Department of Medical Genetics and Genomic Medicine, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
- Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas, Brazil
| | - Iscia Lopes-Cendes
- Department of Medical Genetics and Genomic Medicine, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
- Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas, Brazil
| |
Collapse
|
10
|
Morocco's First Biobank: Establishment, Ethical Issues, Biomedical Research Opportunities, and Challenges. BIOMED RESEARCH INTERNATIONAL 2020; 2020:8812609. [PMID: 33376744 PMCID: PMC7738781 DOI: 10.1155/2020/8812609] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 11/15/2020] [Accepted: 11/18/2020] [Indexed: 02/07/2023]
Abstract
Background Biobanks are highly organized infrastructures that allow the storage of human biological specimens associated with donors' personal and clinical data. These infrastructures play a key role in the development of translational medical research. In this context, we launched, in November 2015, the first biobank in Morocco (BRO Biobank) in order to promote biomedical research and provide opportunities to include Moroccan and North African ethnic groups in international biomedical studies. Here, we present the setup and the sample characteristics of BRO Biobank. Methods Patients were recruited at several departments of two major health-care centers in the city of Oujda. Healthy donors were enrolled during blood donation campaigns all over Eastern Morocco. From each participant, personal, clinical, and biomedical data were collected, and several biospecimens were stored. Standard operating procedures have been established in accordance with international guidelines on human biobanks. Results Between November 2015 and July 2020, 2446 participants were recruited into the BRO Biobank, of whom 2013 were healthy donors, and 433 were patients. For healthy donors, the median age was 35 years with a range between 18 and 65 years and the consanguinity rate was 28.96%. For patients, the median age was 11 years with a range between 1 day and 83 years. Among these patients, 55% had rare diseases (hemoglobinopathies, intellectual disabilities, disorders of sex differentiation, myopathies, etc.), 13% had lung cancer, 4% suffered from hematological neoplasms, 3% were from the kidney transplantation project, and 25% had unknown diagnoses. The BRO Biobank has collected 5092 biospecimens, including blood, white blood cells, plasma, serum, urine, frozen tissue, FFPE tissue, and nucleic acids. A sample quality control has been implemented and suggested that samples of the BRO Biobank are of high quality and therefore suitable for high-throughput nucleic acid analysis. Conclusions The BRO Biobank is the largest sample collection in Morocco, and it is ready to provide samples to national and international research projects. Therefore, the BRO Biobank is a valuable resource for advancing translational medical research.
Collapse
|
11
|
Matzke LA, Watson PH. Biobanking for Cancer Biomarker Research: Issues and Solutions. Biomark Insights 2020; 15:1177271920965522. [PMID: 33192050 PMCID: PMC7594219 DOI: 10.1177/1177271920965522] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 09/17/2020] [Indexed: 12/31/2022] Open
Abstract
Biomarkers are critical tools that underpin precision medicine. However there has been slow progress and frequent failure of biomarker development. The root causes are multifactorial. Here, we focus on the need for fast, efficient, and reliable access to quality biospecimens as a critical area that impacts biomarker development. We discuss the past history of biobanking and the evolution of biobanking processes relevant to the specific area of cancer biomarker development as an example, and describe some solutions that can improve this area, thus potentially accelerating biomarker research.
Collapse
Affiliation(s)
- Lise A Matzke
- Office of Biobank Education and
Research, Department of Pathology and Laboratory Medicine, University of British
Columbia, Vancouver, British Columbia, Canada
- Biobanking and Biospecimen Research
Services, Deeley Research Centre, BC Cancer Agency, Victoria, British Columbia,
Canada
| | - Peter H Watson
- Office of Biobank Education and
Research, Department of Pathology and Laboratory Medicine, University of British
Columbia, Vancouver, British Columbia, Canada
- Biobanking and Biospecimen Research
Services, Deeley Research Centre, BC Cancer Agency, Victoria, British Columbia,
Canada
- Canadian Tissue Repository Network,
Vancouver, Canada
| |
Collapse
|
12
|
Barnes RO, Watson PH. Precision medicine: Driving the evolution of biobanking quality. Healthc Manage Forum 2020; 33:102-106. [PMID: 31957497 DOI: 10.1177/0840470419898874] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The promise of precision medicine will only be realized if the healthcare system adapts to meet some key infrastructure needs. Among these needs are adequate biobanking practices, capable of producing the biological samples and data that precision medicine relies upon in both the research and clinical phases. Within the research domain, there have been significant improvements to biobanking processes over the past two decades, driven by increased understanding of the impact of pre-analytical variability and the critical role of biospecimen and data quality. In the era of precision medicine, biobanking to support clinical needs has similar quality requirements. The extensive knowledge and resources that have been developed by the research biobanking community are available for adoption by clinical biobanking. The challenge and opportunity now presented to the healthcare system is to adopt or adapt these resources, for example, external biobanking standards and verification programs.
Collapse
Affiliation(s)
- Rebecca O Barnes
- Research and Capacity Building, Vancouver Island Health Authority, Victoria, British Columbia, Canada.,Canadian Tissue Repository Network, Vancouver, British Columbia, Canada
| | - Peter H Watson
- Canadian Tissue Repository Network, Vancouver, British Columbia, Canada.,Office of Biobank Education and Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.,Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada
| |
Collapse
|
13
|
Grizzle WE, Bledsoe MJ, Al Diffalha S, Otali D, Sexton KC. The Utilization of Biospecimens: Impact of the Choice of Biobanking Model. Biopreserv Biobank 2019; 17:230-242. [PMID: 31188627 DOI: 10.1089/bio.2019.0008] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The term research "biobank" is one of multiple names (e.g., bioresource, biorepository,) used to designate an entity that receives, collects, processes, stores, and/or distributes biospecimens or other biospecimen-related products (e.g., data) to support research. There are multiple organizational models of biobanking used by bioresources, but the primary goal of all bioresources should not be simply to collect biospecimens, but ultimately to distribute almost all collected biospecimens and/or data to support scientific research; bioresources should serve as "biodistributors" rather than "biovaults." The appropriate choice of model is the first step in ensuring optimal biospecimen utilization by a bioresource. This article discusses some of the different models that may be used alone or in combination by a bioresource providing biospecimens for research; it describes the factors affecting the choice of the most appropriate model or models, the advantages and disadvantages of the various models, and a discussion of the impact of the choice of the model on biospecimen utilization. Frequently, problems with biospecimen utilization are not caused by any single model, but rather a mismatch between the choice of model and goals of the bioresource, and/or problems with the subsequent design, goals, operations, and management of the bioresource after a model is selected.
Collapse
Affiliation(s)
- William E Grizzle
- 1 Department of Pathology and the Comprehensive Cancer Center, The University of Alabama at Birmingham (UAB), Birmingham, Alabama
| | - Marianna J Bledsoe
- 2 Independent Consultant, Deputy Editor, Biopreservation and Biobanking, Silver Spring, Maryland
| | - Sameer Al Diffalha
- 1 Department of Pathology and the Comprehensive Cancer Center, The University of Alabama at Birmingham (UAB), Birmingham, Alabama
| | - Dennis Otali
- 1 Department of Pathology and the Comprehensive Cancer Center, The University of Alabama at Birmingham (UAB), Birmingham, Alabama
| | - Katherine C Sexton
- 1 Department of Pathology and the Comprehensive Cancer Center, The University of Alabama at Birmingham (UAB), Birmingham, Alabama
| |
Collapse
|
14
|
Flügge F, Figge L, Duhm-Harbeck P, Kammler R, Habermann JK. How clinical biobanks can support precision medicine: from standardized preprocessing to treatment guidance. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT 2019. [DOI: 10.1080/23808993.2019.1690395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Friedemann Flügge
- Interdisciplinary Center for Biobanking-Lübeck, University of Lübeck, Lübeck, Germany
| | - Lena Figge
- Interdisciplinary Center for Biobanking-Lübeck, University of Lübeck, Lübeck, Germany
| | | | - Rosita Kammler
- Translational Research Coordination for International Breast Cancer Study Group and European Thoracic Oncology Platform, Bern, Switzerland
- European, Middle Eastern and African Society for Biopreservation and Biobanking, Brussels, Belgium
| | - Jens K. Habermann
- Interdisciplinary Center for Biobanking-Lübeck, University of Lübeck, Lübeck, Germany
- European, Middle Eastern and African Society for Biopreservation and Biobanking, Brussels, Belgium
- Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein (UKSH), Lübeck, Germany
| |
Collapse
|